PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 5, 2023New England Journal of Medicine449 citationsOpen Access

Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma

JWJason R. WestinOOOlalekan O. OluwoleMKMarie José Kersten

Key Points

Key points are not available for this paper at this time.

Abstract

At a median follow-up of 47.2 months, axi-cel as second-line treatment for patients with early relapsed or refractory large B-cell lymphoma resulted in significantly longer overall survival than standard care. (Funded by Kite; ZUMA-7 ClinicalTrials.gov number, NCT03391466.).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Westin et al. (2023) studied this question.

synapsesocial.com/papers/69d77489f44a16d01ef3118fhttps://doi.org/10.1056/nejmoa2301665
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma2023 · 51 citations
  2. 2Outcomes of Axicabtagene Ciloleucel in Comparison with Chemoimmunotherapy (CIT) in an Elderly Population for Treatment of Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) after Two or More Lines of Prior Therapy2022 · 7 citations
  3. 3Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification2014 · 5,701 citations
  4. 4Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma2022 · 78 citations
  5. 5Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial2022 · 289 citations